ClinicalTrials.gg
Active, not recruitingNCT06376136Updated Sep 30, 2026

A Multicenter Open Clinical Study of Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of BAT 8010 for Injection Combined With BAT 1006 in the Treatment of Locally Advanced or Metastatic Tumors

A Phase 1/2 interventional study of BAT8010 for Injection and BAT1006 for Injection in Advanced Solid Tumors, sponsored by Bio-Thera Solutions. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Bio-Thera Solutions · Phase 1/2, Interventional, and Treatment

Updated Sep 30, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
218
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a multicenter, open, exploratory Phase Ib/IIa clinical trial in humans The combination of BAT8010 and BAT1006 was administered in patients with locally advanced or metastatic solid tumors(HER-2 expression, including IHC3+, IHC2+/FISH+, and IHC2+/FISH- patients)Tolerance and PK characteristics, to explore the maximum tolerated dose (MTD) and provide recommendations for subsequent clinical studies Recommended dose (RP2D) and rational administration regimen, and preliminary evaluation of antitumor efficacy. There are two main studies In the first stage, the "3+3" dose escalation rule is proposed to explore the safety and tolerance of the drug Sex; The second stage selects the appropriate dose and administration according to the preliminary safety and efficacy results of the previous stage The drug regimen and tumor species were expanded to further explore the combination of BAT8010 and BAT1006 for injection,The safety and clinical effectiveness of drug administration provided the basis for the follow-up clinical study.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

Bio-Thera Solutions is the lead sponsor of 57 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age ≥18 years old, male and female, voluntarily sign ;
  2. Estimated survival ≥3 months as assessed by the investigators;
  3. the Eastern UnitedStates Cancer Consortium () physicalstatu sscore requirements of 0 to 1 points;
  4. Included in the crowd:

    1. Dose escalation stage: Patients with expression confirmed by histopathology and cytopathology (including IHC3+, IHC2+/FISH+ and IHC2+/FISH-) who have failed standard therapy or have no standard treatment options or are not suitable for standard therapy at this stage, The climbing stage includes but is not limited to breast cancer, stomach cancer, non-small cell lung cancer, biliary tract cancer, colorectal cancer, urothelial carcinoma, etc.
    2. Dose expansion phase: divided into 3 cohorts i. Cohort A: Patients with breast cancer with HER-2 expression (including IHC3+, IHC2+/FISH+ and IHC2+/FISH-) confirmed by histopathology and cytopathology after failure of standard treatment or no standard treatment regimen or unsuitable for standard treatment at this stage; ii. Cohort B: Patients with histopathologically confirmed and inoperable locally advanced or urothelial carcinoma, including urinary bladder, pelvis, ureter, and urethral origin with HER-2 expression (including IHC3+, IHC2+/FISH+, and IHC2+/FISH-); iii. Cohort C: patients with gastric adenocarcinoma (including gastroesophageal junction adenocarcinoma) with disease progression after standard therapy, or or cytologically proven metastatic or unresectable locally advanced or metastatic HER-2 expression (including IHC3+, IHC2+/FISH+, and IHC2+/FISH-) who are intolerant to standard therapy;
  5. the dose escalation phase must have an evaluable tumor lesion, and the dose expansion phase must have at least one measurable tumor lesion (according to 1.1 criteria);
  6. Pregnant women must have a negative pregnancy test during the screening period, before first dosing, and on the first day of each cycle. Consent must be given to the use of effective methods to prevent pregnancy. No egg donation. And willing to take effective contraceptive methods to prevent pregnancy after signing the informed consent until 90 days after the last dosing of the study.

Exclusion criteria

Exclusion Criteria:

  1. During previous treatment with -targeted drugs such as trastuzumab or pertuzumab, T-DM1, vedicitumab or Enhertu, as well as topoisomerase I inhibitors (such as irinotecan), grade 3 aes (including but not limited to infusion reactions or allergic reactions) that were determined to be treaty-related or of unknown drug relationship, or L after treatment VEF \< 50%;
  2. Participants who had previously received doxorubicin with cumulative dose > 360 mg/m2 or equivalent anthracyclines;
  3. Before the first administration of the drug, AE (CTCAE5.0) caused by previous antitumor therapy still had grade 1, except for the following cases: a. Hair loss; b Pigmentation; c. Patients with distal toxicity caused by chemotherapy and radiotherapy who can not be further recovered by judgment;
  4. primary central nervous system tumor or symptomatic central nervous system , meningeal metastasis or a history of epilepsy. Patients with asymptomatic or asymptomatic central nervous system metastases under clinical control or who have symptoms but are judged to be stable by the investigators can be included, provided that the following conditions are met :a. The clinical symptoms were stable ≥4 weeks before the first dose. b. Brain MRI enhancement showed no evidence of progression of central nervous system disease within 4 weeks prior to initial administration; c. Antiepileptic drugs, hormones and other drugs have been stopped ≥2 weeks before the first administration;
  5. Major surgical procedures were performed within 28 days prior to the first use of the study drug, or if postoperative complications persist after 21 days;
  6. Subjects who have had a severe infection within 4 weeks prior to first dosing, or who have any signs and symptoms of active infection within 2 weeks prior to first dosing;
  7. Subjects who have not been treated or are being treated for tuberculosis, including but not limited to tuberculosis (those who have been treated with standardized anti-tuberculosis therapy and have been confirmed cured by the investigator), a history of immunodeficiency, including (HIV) infection, or other immunodeficiency diseases, or a history of organ transplantation;
  8. there are infected with the following diseases: active virus infection [hepatitis B surface antigen (HBsAg) positive, and hepatitis B virus deoxyribonucleic acid (HBV-DNA) test >200 IU/ml or 103 copies /ml (or > the normal high value of the study center detection)]; virus infection [HCV antibody and viral ribonucleic acid (HCV-RNA) test positive]; Treponema pallidum antibody positive and RPR positive;
  9. Patients with symptomatic congestive heart failure ( grade II to IV) or severe arrhythmias requiring treatment (12-lead extension of 450 ms [male], 470 ms [female]), myocardial infarction, unstable angina in the last 6 months. Except atrial fibrillation or paroxysmal supraventricular tachycardia;
  10. Patients with a history of non-infectious pneumonia requiring therapy or with current interstitial lung disease;
  11. the presence of any other serious underlying medical conditions (e.g. Gilbert's syndrome, uncontrolled diabetes, uncontrolled hypertension, active gastric ulcers, uncontrolled seizures, cerebrovascular events, gastrointestinal bleeding, severe signs and symptoms of coagulation and coagulation disorders), psychiatric/psychological/family factors that the investigator determines may influence screening, treatment, and follow-up. Affect compliance or put patients at high risk for treatment-related complications;
  12. The previous anti-tumor therapy (such as chemotherapy, endocrine therapy, targeted therapy, immunotherapy or tumor embolization, etc.) is less than 28 days from the first study (or if the half-life of the drug is 5 times shorter than 28 days, the sponsor and the researcher shall decide whether to include it according to the specific analysis of the specific circumstances). Note that castration for prostate cancer and bisphosphonate or dinomumab for osteoporosis are permitted. Patients whose previous palliative radiotherapy was less than 7 days removed from the first study, or whose previous wide-field radiotherapy was less than 28 days removed from the first study, or who had not recovered from the side effects of radiotherapy as determined by the investigators;
  13. Therapeutic radiopharma use must be discontinued 8 weeks before the first study administration;
  14. Known allergy or intolerance to the investigational drug or its ;
  15. Pregnant or lactating women;
  16. Subjects considered unsuitable for participation in this study by the researcher.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
218 participants (estimated)

Study arms

  • Experimental
    A/ Standard 3+3 2.1mg/kg of BAT8010

    Drug: BAT8010, Dosage: 2.1mg/kg, Frequency: once every 3 weeks, Duration: 1year

    Drug: BAT8010 for Injection

  • Experimental
    B/ Standard 3+3 2.4mg/kg of BAT8010

    Drug: BAT8010, Dosage: 2.4mg/kg, Frequency: once every 3 weeks, Duration: 1year

    Drug: BAT8010 for Injection

  • Experimental
    C/ Standard 3+3 2.7 mg/kg of BAT8010

    Drug: BAT8010, Dosage: 2.7 mg/kg, Frequency: once every 3 weeks, Duration: 1year

    Drug: BAT8010 for Injection

  • Experimental
    Standard 3+3 15 mg/kg of BAT1006

    Drug: BAT1006, Dosage: 15 mg/kg, Frequency: once every 3 weeks, Duration: 1year

    Drug: BAT1006 for Injection

Interventions

  • DrugBAT8010 for Injection

    Intravenous

  • DrugBAT1006 for Injection

    Intravenous

06

What researchers measure

Primary outcomes

  1. Dose-limiting toxicity (DLT)

    DLT events and their incidence.

    Time frame: The first administration cycle(21 days)

  2. vital signs

    Number of participants with abnormal vital signs

    Time frame: Through study completion, 1 year

  3. Physical examination

    Number of participants with abnormal physical examination

    Time frame: Through study completion, 1 year

  4. Adverse events

    Number of cases with all adverse medical events that occur after the subject receives the investigational drug

    Time frame: From the first receipt of the investigational drug until 28 (+7) days after the last receipt of the investigational drug or the initiation of a new antitumor therapy, whichever occurs earlier,assessed up to 1 year

  5. Clinical laboratory tests

    Number of participants with abnormal Clinical laboratory tests

    Time frame: Through study completion, 1 year

  6. Number of participants with abnormal clinical auxiliary tests

    Clinical auxiliary tests

    Time frame: Through study completion, 1 year

  7. Duration of Response(DOR)

    DoR is defined as the time between the first assessment of objective remission of a tumor and death from any cause before the first assessment of Disease progression (PD) , reflecting the duration of ORR

    Time frame: Through study completion, 1 year

  8. Disease Control Rate (DCR)

    The proportion of patients with tumor reduction or stability maintained for a certain period, including cases of complete response (CR), partial response (PR), and stable disease (SD)

    Time frame: Through study completion, 1 year

Secondary outcomes

  1. Pharmacokinetic

    Level of Cmax

    Time frame: At the end of Cycle 1 Day 1 to Cycle 1 Day 4, Cycle 1 Day 8,Cycle 1 Day 15, Cycle 2 Day 1,Cycle 3 Day 1 to Cycle 3 Day 3 , Cycle 3 Day 8 , Cycle 3 Day 15,Cycle 4 Day 1 ,Cycle 5 Day 1 ,Cycle 6 Day 1,EOT until 17 cycles (one cycle equals 2 weeks)

  2. Pharmacokinetic

    Level of Tmax

    Time frame: At the end of Cycle 1 Day 1 to Cycle 1 Day 4, Cycle 1 Day 8,Cycle 1 Day 15, Cycle 2 Day 1,Cycle 3 Day 1 to Cycle 3 Day 3 , Cycle 3 Day 8 , Cycle 3 Day 15,Cycle 4 Day 1 ,Cycle 5 Day 1 ,Cycle 6 Day 1,EOT until 17 cycles (one cycle equals 2 weeks)

  3. Pharmacokinetic

    Level of CL

    Time frame: At the end of Cycle 1 Day 1 to Cycle 1 Day 4, Cycle 1 Day 8,Cycle 1 Day 15, Cycle 2 Day 1,Cycle 3 Day 1 to Cycle 3 Day 3 , Cycle 3 Day 8 , Cycle 3 Day 15,Cycle 4 Day 1 ,Cycle 5 Day 1 ,Cycle 6 Day 1,EOT until 17 cycles (one cycle equals 2 weeks)

  4. Pharmacokinetic

    Level of T1/2

    Time frame: At the end of Cycle 1 Day 1 to Cycle 1 Day 4, Cycle 1 Day 8,Cycle 1 Day 15, Cycle 2 Day 1,Cycle 3 Day 1 to Cycle 3 Day 3 , Cycle 3 Day 8 , Cycle 3 Day 15,Cycle 4 Day 1 ,Cycle 5 Day 1 ,Cycle 6 Day 1,EOT until 17 cycles (one cycle equals 2 weeks)

  5. Antibody

    Level of ADA

    Time frame: At the end of Cycle 1 Day 1, Cycle 2 Day 1,Cycle 3 Day 1 ,Cycle 5 Day 1,Cycle 6 Day 1,EOT until 17 cycles (one cycle equals 2 weeks)

  6. Antibody

    Level of Nab

    Time frame: At the end of Cycle 1 Day 1, Cycle 2 Day 1,Cycle 3 Day 1 ,Cycle 5 Day 1,Cycle 6 Day 1,EOT until 17 cycles (one cycle equals 2 week

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2024 (actual). Primary completion is estimated for Feb 2028, 45 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Nov 2026 → Feb 2028 and completion Dec 2026 → May 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2024
First posted
Apr 19, 2024
StartActual
May 8, 2024
Primary completionEst.
Feb 29, 2028was Nov 2026
CompletionEst.
May 30, 2028was Dec 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 30, 2026
Primary completion
Nov 9, 2026→Feb 29, 2028
Sep 30, 2026
Study completion
Dec 9, 2026→May 30, 2028
Sep 30, 2026
Enrollment
216→218
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Active, not recruiting
    Primary completion Nov 9, 2026→Feb 29, 2028
    Study completion Dec 9, 2026→May 30, 2028
    Enrollment 216→218
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06376136
Responsible party
Sponsor
First posted
Apr 19, 2024
Start date
May 8, 2024
Primary completion
Feb 29, 2028 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Ruihua Xu
principal investigator · Medical Ethics Committee of Sun Yat-sen University Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion